Guo Chen
Guo Chen
E-mail confirmado em biogen.com
Título
Citado por
Citado por
Ano
A landscape of driver mutations in melanoma
E Hodis, IR Watson, GV Kryukov, ST Arold, M Imielinski, JP Theurillat, ...
Cell 150 (2), 251-263, 2012
20462012
Loss of PTEN promotes resistance to T cell–mediated immunotherapy
W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ...
Cancer discovery 6 (2), 202-216, 2016
6222016
Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma
JJ Gartner, SCJ Parker, TD Prickett, K Dutton-Regester, ML Stitzel, JC Lin, ...
Proceedings of the National Academy of Sciences 110 (33), 13481-13486, 2013
1482013
Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma
YNV Gopal, H Rizos, G Chen, W Deng, DT Frederick, ZA Cooper, ...
Cancer research 74 (23), 7037-7047, 2014
1092014
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target
G Chen, N Chakravarti, K Aardalen, AJ Lazar, MT Tetzlaff, B Wubbenhorst, ...
Clinical Cancer Research 20 (21), 5537-5546, 2014
1062014
Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016; 6: 202–216. doi: 10.1158/2159-8290
W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ...
CD-15-0283.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
106
Role and therapeutic potential of PI3K‐mTOR signaling in de novo resistance to BRAF inhibition
W Deng, YN Vashisht Gopal, A Scott, G Chen, SE Woodman, MA Davies
Pigment cell & melanoma research 25 (2), 248-258, 2012
962012
Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations
AD Bucheit, G Chen, A Siroy, M Tetzlaff, R Broaddus, D Milton, P Fox, ...
Clinical Cancer Research 20 (21), 5527-5536, 2014
942014
AKT1 Activation Promotes Development of Melanoma Metastases
JH Cho, JP Robinson, RA Arave, WJ Burnett, DA Kircher, G Chen, ...
Cell reports 13 (5), 898-905, 2015
712015
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance
R Somasundaram, G Zhang, M Fukunaga-Kalabis, M Perego, C Krepler, ...
Nature communications 8 (1), 1-16, 2017
582017
Myeloid lineage of high proliferative potential human smooth muscle outgrowth cells circulating in blood and vasculogenic smooth muscle-like cells in vivo
P Metharom, C Liu, S Wang, P Stalboerger, G Chen, B Doyle, Y Ikeda, ...
Atherosclerosis 198 (1), 29-38, 2008
552008
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor–Refractory Metastatic Melanoma: A Phase 2 Clinical Trial
G Chen, JL McQuade, DJ Panka, CW Hudgens, A Amin-Mansour, XJ Mu, ...
JAMA oncology 2 (8), 1056-1064, 2016
422016
Targeted therapy resistance mechanisms and therapeutic implications in melanoma
G Chen, MA Davies
Hematology/Oncology Clinics 28 (3), 523-536, 2014
282014
Emerging insights into the molecular biology of brain metastases
G Chen, MA Davies
Biochemical pharmacology 83 (3), 305-314, 2012
242012
RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma
L Goedert, CG Pereira, J Roszik, JR Plaça, C Cardoso, G Chen, W Deng, ...
Oncotarget 7 (24), 36711, 2016
212016
Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin
TD Prickett, B Zerlanko, JJ Gartner, SCJ Parker, K Dutton-Regester, ...
Journal of Investigative Dermatology 134 (2), 452-460, 2014
162014
Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular …
JL McQuade, G Chen, DJ Panka, A Reuben, RL Bassett, A Joon, ...
Journal of Clinical Oncology 33 (15_suppl), e20051-e20051, 2015
12015
Molecular and clinical correlates of PTEN expression in melanoma
MA Davies, G Chen, DD Liu, J Malke, JE Gershenwald, AJ Lazar
Cancer Research 72 (8 Supplement), 968-968, 2012
12012
RMEL3, a long noncoding RNA, induces tumor malignancy through the MAPK and PI3K pathways in BRAFV600E melanomas
L Goedert, CG Pereira, J Roszik, JR Plaça, C Cardoso, G Chen, W Deng, ...
Abstracts, 2016
2016
AKT1 activation promotes brain metastasis in a mouse model of melanoma
D Kircher, J Cho, J Robinson, R Arave, R Green, G Chen, M Davies, ...
Clinical Cancer Research 22 (1 Supplement), 37-37, 2016
2016
O sistema não pode executar a operação agora. Tente novamente mais tarde.
Artigos 1–20